Cohance Lifesciences Reports Q1FY27 Results; Anticipates H2 Rebound Following Weak Quarter

Cohance Lifesciences Reports Q1FY27 Results; Anticipates H2 Rebound Following Weak Quarter​

Cohance Lifesciences Limited, formerly Suven Pharmaceuticals Limited, has announced its unaudited financial results for the first quarter ended June 30, 2026. The company reported a challenging quarter, with revenue declining year-on-year, yet management expressed confidence in an anticipated turnaround and growth rebound from the second half of the fiscal year.

The Q1FY27 results show significant operational movement across various business segments as Cohance focuses on its strategic priorities, including building an integrated nucleic acid business and repositioning its agrochemicals portfolio toward a product-led model.

Financial Performance Snapshot​

Cohance reported revenue from operations of ₹4,223 million for the quarter, marking a 23.1% decline year-on-year. Gross margins were 71.5%, having contracted slightly from 73.0% in Q1FY26.

The company’s adjusted EBITDA was ₹92 million, resulting in standalone adjusted EBITDA margins of 9.2%. The standalone business generated revenue of ₹3,599 million and realized an adjusted EBITDA of ₹332 million, maintaining a margin of 9.2%. Sapala contributed approximately ₹274 million to the revenue base, while NJ Bio reported revenues of ₹350 million but recorded an adjusted EBITDA loss.

Management Perspective and Outlook​

Umang Vohra, Executive Chairman and Group CEO, stated that Q1 reflected the guidance, being the company's lowest quarter ever in terms of revenue and EBITDA. He confirmed an expectation of improvement in Q2, leading to a return to year-on-year growth from the second half. This rebound is expected to be supported by secured orders, scheduled deliveries, and progress across the late-stage pipeline.

The CEO highlighted immediate strategic priorities undertaken during the quarter: developing one integrated nucleic acid business with a defined path toward full ownership of Sapala, and repositioning Agrochemicals towards an innovator-product-led portfolio.

Business Segment Highlights​

Operational activity was diverse across Cohance’s segments:

Pharma CDMO & Pipeline:
Two recently commercialized molecules are scheduled for delivery throughout Q2 and Q3. Furthermore, a significant restocking order was secured for a commercial molecule that had been affected by inventory destocking in FY26, providing delivery visibility extending into Q4 FY27 and FY28. The late-stage pipeline advanced with one product reaching Phase III and increased participation in an existing fasttrack Phase III program. RFQ opportunities strengthened across the ADC payload-linker segments and Oligo services.

ADCs:
Execution progressed across payload, payload linker, and bioconjugation programs. A customized payload order is scheduled for Q2 delivery, while customer interest remains encouraging as innovators diversify supply chains for expanded MMAE and Exatecan portfolios.

Nucleic Acids:
Shipments began under a specialized building-block program supporting an orphan-drug candidate. Cohance is integrating its R&D, business development, manufacturing, and commercial execution around an integrated nucleic acid offering anchored in Sapala. GMP operationalization and validation of priority amidites are underway.

API+ and Specialty Chemicals:
The API business remained resilient, supported by pricing and product mix stability. The company secured two CEP approvals and filed two Korean DMFs for additional product grades. Formulations performance was reported as softer, while remediation and operational normalization at Nacharam proceeded according to plan. In Specialty Chemicals, Performance Materials advanced in line with the plan, and an active-ingredient program moved into registration and qualification campaigns with Japanese innovators.

Quality and Sustainability:
In terms of quality execution, multiple customer audits across the Pharma CDMO and API manufacturing network were completed without any critical observations. Commercial On-Time In-Full (OTIF) maintained 100% year to date. Cohance achieved EcoVadis Gold Rating for its sustainability assessment, reflecting strength in environmental, social, and governance performance. Additionally, two of the company’s API sites and two CDMO sites received the British Safety Council International Safety Award 2026 (Merit).

COHANCE Stock Price Movement​

Cohance Lifesciences Limited shares gained on the day, closing at ₹429.45 after edging up 0.82%. The stock traded within a tight range during trading today, touching a low of ₹422.5 and achieving a high of ₹431.9.